Clinical Trial Update: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled study evaluating nabiximols as add-on therapy for spasticity in multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Nabiximols (tetrahydrocannabinol and cannabidiol oromucosal spray)

Snippet

Sponsor: GW Research Ltd | Conditions: Spasticity, Multiple Sclerosis | Phase 3 | Status: WITHDRAWN